- Published at
- by manilatimes.net
neutral
neutral
News for Denali Therapeutics Inc. (DNLI)
- Published at
- by gurufocus.com
positivepositiveBaillie Gifford's Recent Transaction with Denali Therapeutics Inc
On December 31, 2024, Baillie Gifford (Trades, Portfolio) made a significant move in its investment portfolio by reducing its position in Denali Therapeutics In- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
positivepositiveDenali Therapeutics Inc (DNLI) Announces Promising Long-Term Data for Hunter Syndrome Treatment
Summary Denali Therapeutics Inc (DNLI) has released promising long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) for treating Hunter syndrome- Published at
- by gurufocus.com
positivepositiveDenali Therapeutics Inc (DNLI) Announces Key Milestones for 2025
Denali Therapeutics Inc (DNLI), a biopharmaceutical company based in South San Francisco, announced significant milestones for 2025, including the FDA Breakthro- Published at
- by gurufocus.com
positivepositiveDenali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in earl- Published at
- by seekingalpha.com
negativenegativeDenali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI)
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click for my DNLI stock update.- Published at
- by vcnewsdaily.com
positivepositiveTenvie Therapeutics Launches with $200M Funding
SOUTH SAN FRANCISCO, CA, Tenvie Therapeutics launched with $200 million in funding led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital.- Published at
- by gurufocus.com
neutralneutralDenali Therapeutics Inc (DNLI) Announces Topline Results from HEALEY ALS Platform Trial
Denali Therapeutics Inc (DNLI) has released topline results from the Phase 2/3 HEALEY ALS Platform Trial, evaluating the eIF2B agonist DNL343 for the treatment- Published at
- by gurufocus.com
neutralneutralDenali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksO- Published at
- by manilatimes.net
neutralneutral- Published at
- by investing.com
mixedmixedAfter-hours movers: Ulta Beauty, Inari Medical, Meta Platforms and more By Investing.com
After-hours movers: Ulta Beauty, Inari Medical, Meta Platforms and more- Published at
- by investing.com
neutralneutralDenali Therapeutics' ALS study fails to meet primary endpoint; shares fall 19% postmarket By Investing.com
Denali Therapeutics' ALS study fails to meet primary endpoint; shares fall 19% postmarket- Published at
- by benzinga.com
positivepositiveThis Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday - Denali Therapeutics (NASDAQ:DNLI), Elevation Oncology (NASDAQ:ELEV)
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...- Published at
- by globenewswire.com
mixedmixedTau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
The rising incidence of Alzheimer's and other tau-related disorders, driven by an aging global population, is significantly boosting the demand for...- Published at
- by globenewswire.com
mixedmixedGlobal Corporate Wellness Market to Surpass ~USD 117 Billion by 2030 | DelveInsight
The growing demand for corporate wellness is largely driven by factors such as increased screen time, higher workloads, rapid urbanization, poor diet,...- Published at
- by globenewswire.com
mixedmixedGlobal Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...- Published at
- by globenewswire.com
mixedmixedGlobal Neuroendoscopy Market to Exhibit Growth at a CAGR of ~5% by 2030| DelveInsight
The surge in neuroendoscopy demand is chiefly fueled by the increasing occurrence of neurological conditions like brain tumors. Furthermore, the escalating...- Published at
- by globenewswire.com
mixedmixedPDE4 Inhibitor Market to Exhibit Substantial Growth Rate During the Study Period (2020–2034) | DelveInsight
The PDE4 inhibitor market is poised for substantial growth in the coming years, driven by expanding research in inflammatory and autoimmune diseases. With...- Published at
- by globenewswire.com
mixedmixedMotor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The market growth rate is significantly impacted by the rising prevalence of motor neuron disease and the increasing geriatric population. Additionally,...